Cargando…

Antagonistic Effect of a Salivary Proline-Rich Peptide on the Cytosolic Ca(2+) Mobilization Induced by Progesterone in Oral Squamous Cancer Cells

A salivary proline-rich peptide of 1932 Da showed a dose-dependent antagonistic effect on the cytosolic Ca(2+) mobilization induced by progesterone in a tongue squamous carcinoma cell line. Structure-activity studies showed that the activity of the peptide resides in the C-terminal region characteri...

Descripción completa

Detalles Bibliográficos
Autores principales: Palmerini, Carlo Alberto, Mazzoni, Michela, Radicioni, Giorgia, Marzano, Valeria, Granieri, Letizia, Iavarone, Federica, Longhi, Renato, Messana, Irene, Cabras, Tiziana, Sanna, Maria Teresa, Castagnola, Massimo, Vitali, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729474/
https://www.ncbi.nlm.nih.gov/pubmed/26814504
http://dx.doi.org/10.1371/journal.pone.0147925
Descripción
Sumario:A salivary proline-rich peptide of 1932 Da showed a dose-dependent antagonistic effect on the cytosolic Ca(2+) mobilization induced by progesterone in a tongue squamous carcinoma cell line. Structure-activity studies showed that the activity of the peptide resides in the C-terminal region characterized by a proline stretch flanked by basic residues. Furthermore, lack of activity of the retro-inverso peptide analogue suggested the involvement of stereospecific recognition. Mass spectrometry-based shotgun analysis, combined with Western blotting tests and biochemical data obtained with the Progesterone Receptor Membrane Component 1 (PGRMC1) inhibitor AG205, showed strong evidence that p1932 performs its modulatory action through an interaction with the progesterone receptor PGRMC1, which is predominantly expressed in this cell line and, clearly, plays a role in progesterone induced Ca(2+) response. Thus, our results point to p1932 as a modulator of the transduction signal pathway mediated by this protein and, given a well-established involvement of PGRMC1 in tumorigenesis, highlight a possible therapeutic potential of p1932 for the treatment of oral cancer.